Publications by authors named "Elisa Vinci"
Background: The combination of prone positioning and extracorporeal membrane oxygenation (ECMO) in patients with acute respiratory distress syndrome (ARDS) is recognized as safe but its use has been limited due to potential complications.
Aim: To report the prevalence of pressure ulcers and other complications due to prone positioning in adult patients receiving veno-venous ECMO.
Study Design: This cross-sectional study was conducted in a tertiary level intensive care unit (ICU) in Milan (Italy), between January 2015 and December 2019.
Complications of prone positioning in patients with COVID-19: A cross-sectional study.
Intensive Crit Care Nurs
December 2021
Objective: To determine the prevalence of complications in patients with COVID-19 undergone prone positioning, focusing on the development of prone-related pressure ulcers.
Methods: Cross-sectional study conducted in the hub COVID-19 centre in Milan (Italy), between March and June 2020. All patients with COVID-19 admitted to intensive care unit on invasive mechanical ventilation and treated with prone positioning were included.
Article Synopsis
- - The study aimed to evaluate the safety and effectiveness of the Adalimumab biosimilar ABP 501 in patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis, over a one-year period.
- - It included 559 patients divided into three groups based on prior treatment exposure, revealing higher incidences of serious adverse events in those naïve to Adalimumab compared to those switched from the originator drug.
- - Overall, ABP 501 demonstrated similar safety and effectiveness to the original Adalimumab, with a high clinical response and better treatment persistence in patients who switched from the originator.
Background: No data on the recently introduced infliximab (IFX) biosimilar SB2 in inflammatory bowel disease (IBD) are available.
Methods: The Sicilian Prospective Observational Study of Patients With IBD Treated With Infliximab Biosimilar SB2 is a multicenter, observational, prospective study performed among the cohort of the Sicilian Network for Inflammatory Bowel Disease. All consecutive IBD patients starting the IFX biosimilar SB2 from its introduction in Sicily (March 2018) to September 2019 (18 months) were enrolled.